CME
CME Group
$245.20
▼ 0.5%Updated Today 6:01 PM ET
▼ Down 9.5% over the last 12 months
Market Cap
$89.28B
P/E
20.74x
Forward P/E (est.)
17.67x
ROE
15.3%
Revenue Growth
24.6%
EPS Growth
17.4%
Profit Margin
33.7%
FCF Yield
3.6%
Debt / Equity
0.12x
ROIC
13.0%
Interest Coverage
—
Current Ratio
1.02x
Dividend Yield
1.9%
Implied Growth (rev. DCF)
4.1%
Rating Score
81/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what CME's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. CME trades near $245.20, below its 50-day average ($281.58) and 200-day average ($281.78). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 34 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. CME's is $9.44 (~3.8% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month CME found buyers near $244.56 (support) and sellers near $301.91 (resistance); its 52-week range is $244.56–$329.16. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.7× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
CME Group (CME) is a large-cap company in the Financial Exchanges & Data industry, part of the Financials sector of the S&P 500, with a market value around $89.28B.
In its latest reported year it generated about $6.52B in revenue and $4.07B in net profit.
Our model rates CME Strong (81/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
8.6%
Revenue moved from $4.69B in 2021 to $6.52B in 2025, a 8.6% compound annual growth rate. The most recent year grew a strong 24.6% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
96.0%
Operating Margin
64.9%
Net Margin
62.5%
ROE
15.3%
CME Group keeps about 33.7% of each sales dollar as net profit, with a 96.0% gross margin and 64.9% operating margin. Return on equity is 15.3% and return on invested capital about 13.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0.12x
Leverage: debt-to-equity is 0.1x, with a current ratio of 1.0x. That is a conservative balance sheet — a cushion in downturns.
Operating CF
$4.28B
Free Cash Flow
$4.19B
FCF Margin
64.3%
In the latest year CME Group produced about $4.28B of operating cash flow and $4.19B of free cash flow after capital spending. That is a free-cash-flow yield of about 3.6% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
20.74x
P/S
7.87x
P/B
3.23x
EV / EBITDA
21.31x
CME trades at 20.7x trailing earnings (about 17.7x on estimated forward earnings), 7.9x sales, and 3.2x book value. Reverse-engineering today's price implies the market expects roughly 4.1% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How CME stacks up against its Financials peers — valuation, profitability, and growth versus the sector median.
In the Financials sector (76 S&P 500 companies), CME ranks #4 of 76 by our overall rating. It trades at a premium versus the sector on earnings (20.7x P/E vs. 15.2x median) with a similar return on equity (15.3% vs. 15.3%) and faster revenue growth (24.6% vs. 9.1%).
P/E vs sector
20.7x
median 15.2x
ROE vs sector
15.3%
median 15.3%
Growth vs sector
24.6%
median 9.1%
Sector rank
#4
of 76 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Financials companies by sub-industry and size. Sector median is across all 76 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$1,940.85 – $3,135.22
vs. $245.20 today · expected CAGR 51% – 66%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $8.15B | $10.19B | $12.74B | $15.92B | $19.90B |
| Net income | $4.08B | $5.09B | $6.37B | $7.96B | $9.95B |
| EPS | $61.15 | $76.44 | $95.55 | $119.44 | $149.30 |
| Share price (low) | $794.97 | $993.72 | $1,242.15 | $1,552.68 | $1,940.85 |
| Share price (high) | $1,284.19 | $1,605.23 | $2,006.54 | $2,508.18 | $3,135.22 |
| CAGR (low–high) | 224% / 424% | 101% / 156% | 72% / 102% | 59% / 79% | 51% / 66% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CME:
- Revenue is growing 24.6% a year, a sign of real demand.
- High net margins (33.7%) point to pricing power or efficiency.
- Strong return on equity (15.3%) shows capital is put to work well.
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
- Our model's overall read is Strong (81/100).
The case against CME:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: CME Group is a large-cap financials business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 20.7x earnings, which our model scores Strong (81/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.